Juno Therapeutics

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.


Arch Venture Partners plans to fund “wild-ass ideas” with new, $400 million venture fund

Tech venture behemoth Arch Venture Partners has announced its eighth venture fund just closed with more than $400 million in subscriptions and, as co-founder and managing director Robert Nelson just told Forbes, it’s looking to fund companies with “contrarian philosophies.” Alex Konrad over at Forbes writes: That money will go to funding companies that cofounder and […]

Cancer immunotherapy developer Juno adds fresh capital to close $176M Series A

Underscoring the hot investment prospects of cancer immunotherapy, Juno Therapeutics has secured additional funding from investors to close its Series A at $176 million, according to a company statement. The company is developing two immunotherapy platforms to treat hematologic and solid tumor cancers and reduce the toxicity associated with chemotherapeutics. The completion of the A […]